Recruiting PHASE2 Prostate

New treatment option for Prostate

Official title POSLUMA® (18F-rhPSMA-7.3) PET-CT for PIRADS 2/3 Lesions

ClinicalTrials.gov ID: NCT07220720

What this study is testing

What is Flotufolastat F 18?

Flotufolastat F 18 is an investigational medicine, being studied as a potential treatment for prostate.

Also referred to as (18)F-rhPSMA-7.3, POSLUMA.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The goal of this study to determine if using the (18)F-rhPSMA-7.3 PET-CT scan can improve the ability to spot serious prostate cancer in patients who have uncertain MRI results. These uncertain results include MRI results that showed a PIRADS 2 or PIRADS 3 area on the prostate.
  • Phase 2: a mid-size study of how well it works

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 18 to 100, men only

You may be able to join if

  • The patient is willing to provide signed informed consent and is able to comply with all required study-related procedures, where safe and feasible.
  • The patient is male and at least 18 years of age.
  • The patient has not previously undergone a prostate biopsy.
  • The patient underwent a pelvic mpMRI within the last 90 days for the detection of potential prostate cancer (Pca).
  • The patient is a candidate for a targeted MRI/US biopsy and is scheduled to undergo the procedure. Only patients scheduled for a biopsy before...

You likely can't join if

  • Patients with a prior diagnosis of prostate cancer.
  • Patients with any medical condition or circumstance that, in the investigator's opinion, could compromise the study data or prevent the patient from...
  • Patients participating in another treatment clinical trial within the past 30 days.
  • Patients with known hypersensitivity to the active substance or any excipients of flotufolastat F 18 PET-CT.
See the full eligibility criteria
Who can join
  • The patient is willing to provide signed informed consent and is able to comply with all required study-related procedures, where safe and feasible.
  • The patient is male and at least 18 years of age.
  • The patient has not previously undergone a prostate biopsy.
  • The patient underwent a pelvic mpMRI within the last 90 days for the detection of potential prostate cancer (Pca).
  • The patient is a candidate for a targeted MRI/US biopsy and is scheduled to undergo the procedure. Only patients scheduled for a biopsy before recruitment will be considered candidates.
  • The patient has PIRADS 2 and/or PIRADS 3 lesions detected by a board-certified radiologist.
What rules you out
  • Patients with a prior diagnosis of prostate cancer.
  • Patients with any medical condition or circumstance that, in the investigator's opinion, could compromise the study data or prevent the patient from fulfilling the study requirements.
  • Patients participating in another treatment clinical trial within the past 30 days.
  • Patients with known hypersensitivity to the active substance or any excipients of flotufolastat F 18 PET-CT.

The study team makes the final eligibility decision.

Where it's taking place

  • Jacksonville, Florida, United States

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling male, 18 years to 100 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Jacksonville, Florida, United States. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.